Journal article
Abstract 11497: Mineralocorticoid Receptor Antagonists and Atrial Fibrillation: A Systematic Review and Meta-Analysis
Abstract
Introduction:
Medical therapies to prevent atrial fibrillation (AF) episodes and to reduce heart failure (HF) or cardiovascular (CV) death in patients with AF are limited. The role of mineralocorticoid receptor antagonists (MRAs) in this population is unclear.
Authors
Oraii A; Kowalik K; Pandey AK; Benz AP; Wong JA; Conen D; Healey JS; McIntyre WF
Journal
Circulation, Vol. 146, No. Suppl_1, pp. a11497–a11497
Publisher
Wolters Kluwer
Publication Date
November 8, 2022
DOI
10.1161/circ.146.suppl_1.11497
ISSN
0009-7322